Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.
Zhou X, An J, Kurilov R, Brors B, Hu K, Peccerella T, Roessler S, Pfütze K, Schulz A, Wolf S, Hohmann N, Theile D, Sauter M, Burhenne J, Ei S, Heger U, Strobel O, Barry ST, Springfeld C, Tjaden C, Bergmann F, Büchler M, Hackert T, Fortunato F, Neoptolemos JP, Bailey P.
Zhou X, et al. Among authors: burhenne j.
Nat Cancer. 2023 Sep;4(9):1362-1381. doi: 10.1038/s43018-023-00628-6. Epub 2023 Sep 7.
Nat Cancer. 2023.
PMID: 37679568
Free PMC article.